Hypnotics

Washington Poison Center warns parents of continued dangers with the Benadryl™ Challenge

Retrieved on: 
Monday, November 23, 2020

Diphenhydramine is an antihistamine commonly found in over-the-counter sleep aids, cough and cold medications, and allergy medicationsmost notably the brand name Benadryl.

Key Points: 
  • Diphenhydramine is an antihistamine commonly found in over-the-counter sleep aids, cough and cold medications, and allergy medicationsmost notably the brand name Benadryl.
  • It is typically stored in an unsecured or unlocked cabinet, and bulk quantities are available for purchase.
  • WA Poison Center Cases of intentional self-harm or suicidal intent in adolescents ages 13-17 has increased 5% since 2019, and cases of abuse have increased 34%.
  • For questions or emergencies involving diphenhydramine or other potentially harmful substances, call the Washington Poison Center (1-800-222-1222).

ESPAD Report 2019 — Results from the European School Survey Project on Alcohol and Other Drugs

Retrieved on: 
Thursday, November 12, 2020

This report presents the results of the seventh ESPAD data-collection wave, conducted in 35 countries during the spring and autumn of 2019.

Key Points: 
  • This report presents the results of the seventh ESPAD data-collection wave, conducted in 35 countries during the spring and autumn of 2019.
  • It paints a comprehensive picture of the present situation among 1516-year-old school students as regards the use of cigarettes, alcohol, illicit drugs, inhalants, new psychoactive substances and pharmaceuticals, as well as providing insights into gambling, social media use and gaming.
  • The report offers an overview of trends for the period 1995-2019.

Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference

Retrieved on: 
Monday, November 9, 2020

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST).

Key Points: 
  • WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST).
  • The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Companys web site, http://ir.minervaneurosciences.com .
  • Minervas portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinsons disease.
  • Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV.For more information, please visit www.minervaneurosciences.com .

Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Retrieved on: 
Wednesday, September 9, 2020

WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 at 10:00 a.m. Eastern Time.

Key Points: 
  • WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 at 10:00 a.m. Eastern Time.
  • The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Companys web site, http://ir.minervaneurosciences.com .
  • Minervas portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinsons disease.
  • Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV.For more information, please visit www.minervaneurosciences.com .

Isobutanol Market to Reach USD 1555.8 Million By 2027 | CAGR: 6.4% | Reports And Data

Retrieved on: 
Wednesday, September 2, 2020

NEW YORK, Sept. 2, 2020 /PRNewswire/ -- The Global Isobutanol Market is forecast to reach USD 1555.8 Million by 2027, according to a new report by Reports and Data.

Key Points: 
  • NEW YORK, Sept. 2, 2020 /PRNewswire/ -- The Global Isobutanol Market is forecast to reach USD 1555.8 Million by 2027, according to a new report by Reports and Data.
  • Isobutanol's introduction as a synthetic medium for the development of isobutyl esters has also led to market penetration.
  • Isobutanol-associated intrinsic characteristics such as medium volatility and minimal miscibility are considered to be favorable for market growth.
  • For the purpose of this report, Reports and Data has segmented the Global Isobutanol Market on the basis of product, distribution channel, application, and region:

Isobutanol Market to Reach USD 1555.8 Million By 2027 | CAGR: 6.4% | Reports And Data

Retrieved on: 
Wednesday, September 2, 2020

- Market Size USD 977.3 Million in 2019, Market Growth - CAGR of 6.4%, Market Trends growing downstream industries

Key Points: 
  • - Market Size USD 977.3 Million in 2019, Market Growth - CAGR of 6.4%, Market Trends growing downstream industries
    NEW YORK, Sept. 2, 2020 /PRNewswire/ -- The Global Isobutanol Market is forecast to reach USD 1555.8 Million by 2027, according to a new report by Reports and Data.
  • Isobutanol's introduction as a synthetic medium for the development of isobutyl esters has also led to market penetration.
  • Isobutanol-associated intrinsic characteristics such as medium volatility and minimal miscibility are considered to be favorable for market growth.
  • For the purpose of this report, Reports and Data has segmented the Global Isobutanol Market on the basis of product, distribution channel, application, and region:

Eisai to Present Latest Insomnia Research, Including Data on New Treatment DAYVIGO™ (lemborexant) CIV, at the SLEEP 2020 Virtual Conference

Retrieved on: 
Monday, August 24, 2020

Additional research to be presented will explore sleep onset and sleep maintenance responder profiles over 12 months of treatment with DAYVIGO, efficacy and safety of DAYVIGO in females of perimenopausal age with insomnia disorder, and impact of DAYVIGO treatment on fatigue severity.

Key Points: 
  • Additional research to be presented will explore sleep onset and sleep maintenance responder profiles over 12 months of treatment with DAYVIGO, efficacy and safety of DAYVIGO in females of perimenopausal age with insomnia disorder, and impact of DAYVIGO treatment on fatigue severity.
  • In addition, interim results from a multi-center pilot study evaluating the next-dose transition from zolpidem to DAYVIGO for the treatment of insomnia will be presented.
  • DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • CNS depressant effects may persist in some patients up to several days after discontinuing DAYVIGO.

Celebrate National Relaxation Day With Sippin Syrup - The King of Relaxation

Retrieved on: 
Tuesday, August 11, 2020

Everyone should take a deep breath as they count down the days until National Relaxation Day , which is this Saturday, Aug. 15.

Key Points: 
  • Everyone should take a deep breath as they count down the days until National Relaxation Day , which is this Saturday, Aug. 15.
  • Katalyst Beverage suggests that you drink Sippin Syrup, the anti-energy drink that is the king of relaxation, to celebrate this day of calm and tranquility.
  • It was hard for people to find the time to relax, which is why we developed Sippin Syrup.
  • For more information about Sippin Syrup or to purchase Sippin Syrup, visit Amazon.

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020

Retrieved on: 
Wednesday, July 22, 2020

Regarding BAN2401, the clinical study design of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients will be presented orally.

Key Points: 
  • Regarding BAN2401, the clinical study design of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients will be presented orally.
  • The safety and efficacy results from a Phase II clinical study on lemborexant (orexin receptor antagonist) targeting Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with AD will be presented.
  • Finally, they will hold a discussion on the future outlook of this classification system for Alzheimer's pharmacological trials and clinical practice.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Copyright 2020 JCN Newswire .

Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan

Retrieved on: 
Monday, July 6, 2020

2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020.

Key Points: 
  • 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020.
  • DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
  • (9)
    Through the launch of DAYVIGO, Eisai will continue to prioritize the provision of appropriate usage and safety information.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120
    Copyright 2020 JCN Newswire .